Clinical Trials Browser

Carcinoma, Renal Cell × tislelizumab × 90 days × Clear all

NCT05661955 2026-05-11

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1/2 Active not recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma